NON-INVASIVE, TISSUE BASED DIAGNOSTICS
HERA biotech
Diagnosing Endometriosis and Cervical Cancer—In Tissue.
On Time. For Her.
As Seen In
Advancing Women's Health
ABOUT US
Disease Detection Shouldn’t Take Years
Especially When the Answers Are Already in the Tissue
Hera delivers non-invasive, tissue-based diagnostics that replace guesswork with clarity and delays with decisions that fit real-world care. Our AI-powered platform supports endometriosis detection and staging, along with point-of-care cervical diagnosis, integrated seamlessly into OB-GYN, fertility, and drug discovery workflows.
For patients, it means an end to years of dismissal—replaced by trust, relief, and confirmation they can finally act on.
For clinicians, it means faster decisions, built on deep science and tools designed for frontline care.
Have any questions? contact@herabiotech.com
BY THE NUMBERS
Too Common to Be Ignored.
Too Delayed to Be Defended.
0
Women affected by endometriosis
0
Average endometriosis diagnostic delay
0
Annual cervical cancer diagnoses
0
Annual global deaths
Hera accelerates diagnosis, bringing clinical certainty faster to the women who’ve waited long enough.
From fragmented care to inconclusive procedures, the diagnostic journeys for endometriosis and cervical cancer are slow, invasive, costly, and often miss the mark.
These conditions are underdiagnosed, underfunded, and devastating to quality of life.
Practice-Ready. Outcome-Proven.
Built to Lead AI-Powered Women's Health Diagnostics
Our tools exceed today’s standards—and finally match the speed and accuracy patients deserve.
A non-invasive test for endometriosis detection and staging, poised to replace surgery as the gold standard.
0
Specificity
Results in days
A non-invasive, point-of-care cervical cancer diagnostic device for detecting CIN2+ lesions and above.
0
Sensitivity
Real-time results
Fixing the Diagnostic Gap in Chronic Gynecologic Conditions
From validation to deployment, Hera is setting new standards in non-invasive diagnostics—backed by real data, global expansion, and the deepest scientific footprint in women’s health.
Clinician Demand Confirmed
MetriDx selected by top clinics in the space
Commercial Access Secured
HeraFem launching across Latin America in 2025 via COFEPRIS-cleared partners
AI That Gets Smarter with Every Scan
Algorithms trained on real tissue, not symptom reports
7 Patents Across Diagnostic Modalities
Spanning biomarkers, RNA-seq, and optical and electrical spectroscopy technologies
Deepest Endometriosis Pipeline
14B data points, 1K+ samples, and 3 proprietary datasets powering early detection
TRUSTED by PROFESSIONALS
What Diagnostics Should’ve Delivered From the Start
Built by Experts.
25% of Hera’s investors are medical doctors and doctoral-level researchers, underscoring deep alignment between our platform and the physicians who use it.
Making Early Diagnosis Accessible
Access isn’t theoretical—it’s critical. Hera’s non-invasive diagnostics close that gap—deployable through point-of-care and lab workflows, with reimbursement codes and LDT pathways already in motion.
Pioneering New Markets
We’re not just building diagnostics. We’re restoring access to biological truth - geographically, financially, and system-wide. This isn’t just diagnostics reimagined. It’s biology, respected.